Index

A
Abnormal doctoring behavior, 140–141
Abnormal illness behavior, 139–140
Acupuncture, 103–104
African Palliative Care Association’s (APCA) African Palliative Outcome Scale (POS), 150
Alcohol Use Disorders Identification Test (AUDIT), 84
American Pain Society-American Academy of Pain Medicine (APS-AAPM), 113
Anticonvulsants, 100–101
Antidepressants, 100–101
Antiretroviral nonadherence, 117
Antiretrovirals with methadone, 162
Antiretroviral therapy (ART), 28, 52, 63, 113
Audio-guided computer-assisted self-interview (ACASI) format, 84
AUDIT. See Alcohol Use Disorders Identification Test (AUDIT)

B
Behavioral therapies, 101–102
Bipolar disorder, 73
Bowel dysfunction, 116

C
CAM. See Complementary and alternative therapies (CAM)
Cardiovascular disease, 116
cART. See Combination antiretroviral therapy (cART)
Central sensitization, 11–12
Cerebral vasculature
  ischemic and hemorrhagic stroke, 40–41
  posterior reversible encephalopathy syndrome (PRES), 41
  reversible cerebral vasoconstriction syndrome (RCVS), 40
Chiropractic manipulation, 106–107
Chronic low back pain, 31–32
Chronic pain syndromes, 97–108
  behavioral therapies, 101–102
  biologically based CAM, 107–108
  complementary and alternative therapies (CAM), 103–104
  exercise therapy, 102
  interventions and efficacy, 100–101
  manipulative body-based medicine, 106–107
  mind–body medicine, 104–106
neurobiologic and behavioral rationales, 98–99
nonpharmacological approaches, 101–102
pharmacological approaches, 100–101
transcutaneous electrical stimulation (TENS), 102
treatment outcomes, 99
Chronic widespread pain, 32–33
Cognitive behavioral therapy (CBT), 58
Combination antiretroviral therapy (cART), 97
Communication, 16–24
  about diagnostic testing, 22–23
  assessment, 20
  continuity of care, 23–24
  discussing possible referrals, 23–24
  effective communication, 18–19
  family and social support, 24
  less effective communication, 18
  open-ended questions, 19–20
  patient–provider communication, 18
  with patients, 16–18
  poor communication, 18
  psychiatric illness and/or addiction, 21–22
  scheduling follow-up, 23–24
  structured assessment tools, 20
Complementary and alternative therapies (CAM)
  acupuncture, 103–104
  dietary supplements, 107–108
  energy medicine, 104

D
Daily headache, 47–48
Dietary supplements, 107–108
Difficult patient, 137–148
  abnormal doctoring behavior, 140–141
  abnormal illness behavior, 139–140
  behavior, 137–138
  behaviorally based approaches
    assessment of progress, 146
    diagnosis, 145–146
    evaluation, 145
    goals of treatment, 146–147
    patient preference and satisfaction, 147–148
    role induction, 145–146
    treat comorbid conditions, 146
    treatment plan, 145–146
    comorbid conditions in, 144
    conditioning, 138–139
    DSM-V, 143–144

Edited by Jessica S. Merlin, Peter A. Selwyn, Glenn J. Treisman and Angela G. Giovanniello.
© 2016 John Wiley & Sons, Ltd. Published 2016 by John Wiley & Sons, Ltd.

177
178  Index

Difficult patient (continued)
personality and behavior, 144
personality traits, 141–143
Disparities and barriers, 165–172
biopsychosocial model for chronic pain, 167–169
healthcare system factors, 169
lack of trust, 167
pain
assessment and management, 166, 169
experience in, 165–166
underestimation and undertreatment of, 166–167
patient-level interventions, 171
prevalence of, 165
provider level interventions, 169–170
system-level interventions, 171–172
Dorsal root ganglion (DRG), 8
Drug–drug interactions
end of life, 161, 162
opioid prescribing, 117
peripheral neuropathy, 56, 57

E
Endocrine dysfunction, 116
End of life, 157–163
antiretroviral therapy, 161
drug–drug interactions, 161, 162
effective pain management, 158
ethical issues, 163
medication history, 159
mortality rates, 157–158
neurotoxicity, 161–163
opioids uses, 160
pain assessment, 158–159
palliative sedation, 163
pharmacotherapy, 159
prevalence, 157
routes, 159–161
total pain management, 158
Energy medicine, 104
Epidemiology, 1–4
etiology, 2–3
HAART era, 2
HIV epidemic, 1–2
impact, 3–4
Exercise therapy, 102

F
Fibromyalgia, 32–33

H
HAART. See Highly active antiretroviral therapy (HAART)
Headache, 38–48. See also Migraine
cerebral vasculature, 40–41
neuralgias, 46–47
patient with daily headache, 47–48
primary headaches, 42–46
related to infections, 39–40
secondary headaches, 39
treatment and procedures, 41–42
treatment, tracking response to, 48
workup of complaint, 38–39
Health Resources and Services Administration (HRSA), 153–154
Highly active antiretroviral therapy (HAART), 1, 2
HPAIN (headache "red flags"), 38, 39
HRSA. See Health Resources and Services Administration (HRSA)
Hypnosis, 105
I
Immune reconstitution inflammatory syndrome (IRIS), 40
International Association for the Study of Pain (IASP), 7
Ischemic and hemorrhagic stroke, 40–41

M
Manipulative body-based medicine
massage therapy, 107
spinal manipulative therapy (SMT), 106
Massage therapy, 107
Medical comorbid conditions
chronic pain management, 65–68
multimorbidity
and pain management complexity, 64–65
prevalence of, 63
Medication overuse headache (MOH), 41–42
Medication side effects, 41
Meditation, 104–105
MEDUs. See Morphine-equivalent dose units (MEDUs)
Migraine
chronic migraine, 45–46
complications, 46
nonpharmacological and complementary therapy, 45
preventive therapy, 43–45
rescue and bridge therapy, 43
risk factors for, 45
treatment of, 42–43
Mind–body medicine
biofeedback, 106
hypnosis, 105
meditation, 104–105
yoga, 105–106
MOH. See Medication overuse headache (MOH)
Morphine-equivalent dose units (MEDUs), 124
Multimorbidity, 63–68
chronic pain management, 65–68
case studies, 66–68
and pain management complexity
aging, 64
cognitive impairment, 64–65
HIV infection and chronic inflammation, 64
obesity, 64
polypharmacy, 65
prevalence of, 63
Musculoskeletal pain, 27–34
clinical manifestations, 28–29
diagnostic and treatment approaches, 29–31
joint and bone, painful disorders of, 30–31
muscle, painful disorders of, 29–30
syndromes, 31–33
epidemiology, 27
underlying mechanisms, 27–28
Myofascial pain syndrome, 33
Neuralgias
pseudotumor cerebri/idiopathic intracranial hypertension (IIH), 47
trigeminal autonomic cephalalgias (TAC), 46–47
trigeminal neuralgia, 47
Neuropathic pain, 57

Opioid-induced neurotoxicity (OIN), 161, 163
Opioid prescribing, 113–118
benefit, 113–118
and clinical pharmacology, 114
considerations in, 117–118
current research and guidelines, 130
dosing thresholds and referral, 118
drug–drug interactions, 117
epidemiology of, 113
guideline-recommended indications for, 113–114
harms, 113–118
high-risk use, 129–130
indications for, 113–114
initial assessment, 124–125
injury, 115–116
mechanisms of, 114
medical complications
antiretroviral nonadherence, 117
bowel dysfunction, 116
cardiovascular disease, 116
diabetes mellitus, 116
epidermis dysfunction, 116
HIV progression, 117
HIV-specific concerns, 117
immunosuppression, 117
mortality, 117
opioid use disorders, 117
respiratory changes, 116
multidisciplinary staff, 130
ongoing monitoring, 125–126
potential benefit of, 114–115
potential harms of, 115
prescription monitoring programs (PMPs), 128–129
risk assessment principles, 124
safer prescribing, 123–130, 134–136
standard care, 130
type and formulation, 118
unintentional overdose and death, 115
urine drug testing (UDT), 127–128
use of, 123–124
written treatment agreements, 126–127

Pathophysiologic, 7–14
acute pain response, 8–13
central sensitization, 11–12
chronic pain, 11
chronic pain in patients with HIV, 12–13
modulation, 10–11
pain sensory system, 7–8
pain treatment, implications for, 13
peripheral sensitization, 11
primary afferent neurons, 8–9
spinal neurons, 9–10
supraspinal neurons, 10
Periaqueduct gray (PAG) matter, 10
Peripheral neuropathy, 51–59
children, 54
clinical features, 53–54
diagnosis, 54–55
epidemiology, 51–52
impact and comorbidities, 54
management
antidepressant medications, 58
antiepileptic medications, 56, 58
drug–drug interactions, 56, 57
medications for, 56, 57
modifiable risk factors, 56
nonpharmacologic therapy, 58–59
NSAIDs and acetaminophen, 58
symptomatic treatment, 56–59
topical treatment options, 58
pain pathogenesis, 52–53
resource-limited settings, 53–56
risk factors, 53
Peripheral sensitization, 11
Persistent postinfectious headache, 40
Postdural puncture headache, 41
Posterior reversible encephalopathy syndrome (PRES), 41
Posttraumatic stress disorder (PTSD), 166
Prescription monitoring programs (PMPs), 128–129. See also Opioid prescribing
Primary afferent neurons, 8–9
Primary headaches. See also Headache
migraine, 42–46
and neuralgias, 46–47
tension type, 42
Pseudotumor cerebri/idiopathic intracranial hypertension (IIH), 47
Psychiatric comorbidities, 71–75
depression and chronic pain, 72–73
exacerbate chronic pain, 71–72
life experiences, 73–74
identification and treatment, 72–73
Respiratory changes, 116
Reversible cerebral vasoconstriction syndrome (RCVS), 40
Schizophrenia, 73
Secondary headaches, 39
Selective serotonin reuptake inhibitors (SSRIs), 100
Septic thrombosis, headache, 40
Serotonin–noradrenaline reuptake inhibitors (SNRIs), 58
Serotonin–norepinephrine reuptake inhibitor (SNRI), 32
Spinal manipulative therapy (SMT), 106
Spinal neurons, 9–10
Sub-Saharan Africa, HIV-related pain in
concept of pain, 150–151
drug availability, 153
epidemiology of, 150
Health Resources and Services Administration (HRSA), 153–154
Sub-Saharan Africa, HIV-related pain in (continued)
measurement of pain, 152–153
pain management and advocacy, 153
prevalence and correlates, 151
public and patient preferences, 152
resources, 153
Substance use, 78–90
challenges for, 81–82
epidemiology of, 80
experience of, 80–81
guidance for, 82–90
language of, 78–79
Supraspinal neurons, 10

T
Transcutaneous electrical stimulation (TENS),
102
Transient receptor potential vanilloid (TRPV1), 58
Tricyclic antidepressants (TCA), 100
Trigeminal autonomic cephalalgias (TAC), 46–47
Trigeminal neuralgia, 47

V
Vulnerable populations with HIV infection, 165–172
biopsychosocial model for chronic pain, 167–169
healthcare system factors, 169
lack of trust, 167
pain
assessment and management, 166, 169
experience in, 165–166
underestimation and undertreatment of, 166–167
patient-level interventions, 171
prevalence of, 165
provider level interventions, 169–170
system-level interventions, 171–172

Y
Yoga, 105–106